ESMO 2024: Adjuvant Durvalumab Significantly Improved Survival in Limited-Stage SCLC
The PD-L1 inhibitor extended overall survival by 22.4 months compared with placebo
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.